Trial Profile
Phase I study of the safety and persistence of 0.1% UC-781 vaginal gel in HIV-1 seronegative women
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Apr 2012
Price :
$35
*
At a glance
- Drugs UC 781 (Primary)
- Indications HIV infections
- Focus Pharmacokinetics
- 10 Apr 2012 Results published in the Journal of acquired immune deficiency syndromes (1999).
- 03 Mar 2009 Status changed from recruiting to completed, as reported by ClincialTrials.gov.
- 25 Sep 2008 Planned end date changed to 1 Apr 2009.